Roth Comments on Pharmacyclics (PCYC) Following Publication on New Imbruvica Data
Tweet Send to a Friend
Roth Capital affirms Pharmacyclics Inc. (Nasdaq: PCYC) at Buy with a price target of $188 following publication of strong new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
